5Walsh T J, Anaissie E J, Denning D W, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America [J]. Clin Infect Dis, 2008,46(3) :327 - 360.
6Kedzierska A, Koehan P, Pietrzyk A, et al. Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans: galactomannan, mannan and 1-3-bete-D-glucan antigens [J]. Eur J Clin Mierobiol Infect Dis, 2007,26:755 - 766.
7Maertens J, Deeren D, Dierickx D, et al. Preemptive antifungal therapy: still a way to go [J]. Curr Opin Infect Dis,2006, 19(6) :551 - 556.
8Herbrecht R, Berceanu A. Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients?[J]. Clin Infect Dis,2008,46:886-889.
9Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study [J]. Clin Infect Dis,2005, 41 (9):1242 - 1250.
2[1]Rees JR,Pinner RW,Hajjeh RA,et al.The epidemiological features of invasive mycotic infections in the SanFrancisco Bay area,1992-1993:results of population-based laboratory active surveillance[J].Clin Infect Dis,1998,27(5):1138-1147.
3[2]Kao AS,Brandt ME,Pruitt WR,et al.The epidemiology of candidemia in two United States cities:results of a population-based active surveillance[J].Clin Infect Dis,1999,29(5):1164-1170.
5[4]Hajjeh RA,Sofair AN,Harrison LH,et al.Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program[J].J Clin Microbiol,2004,42(4):1519-1427.
6[5]Kedzierska A,Kochan P,Pietrzyk A,et al.Current status of fungal cell wall components in the immunodiagnostics of invasive fungal infections in humans:galactomannan,mannan and 1-3-beta-D-glucan antigens[J].Eur J Clin Microbiol Infect Dis,2007,26(11):755-766.
7[6]Ascioglu S,Rex JH,de Pauw B,et al.Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants:an international consensus[J].Clin Infect Dis,2002,34(1):7-14.
8[7]EORTC/BAMSG Consensus Revised definitions draft VI.http://www.doctorfungus.org/lecture/EORTC_MSG_rev06.htm[DB/OL].Accessed on Dec,23,2007.
9[10]Pappas PG,Rex JH,Sobel JD,et al.Guidelines for treatment of candidiasis[J].Clin Infect Dis,2004,38(2):161-189.
10[11]Gilbert DN,Moellering RC,Sande MA.The Sanford guide to antimicrobial therapy[M].Antimicrobial Therapy Inc,37th ed,Sperryville VA USA,2007:94-99.
